Wegmans is set to open this Sunday at the Brooklyn Navy Yard in New York City. Edward McLaughlin, emeritus professor of food industry management, says given Wegmans’ supermarket innovation in service and products, New York City will now be able to relish in the legendary service, restaurant-quality prepared foods and wide selection of goods that are the envy of supermarket companies around the globe.
A patient living with HIV who received a blood stem cell transplant for high-risk acute myeloid leukemia has been free of the virus for 14 months after stopping HIV antiretroviral drug treatment, suggesting a cure, according to the Weill Cornell Medicine and New York-Presbyterian physician-scientists who performed the transplant and managed her care.
Researchers at Weill Cornell Medicine have identified significant differences in the molecular characteristics of tumors from younger and older cancer patients across several cancer types.
Weill Cornell Medicine has received a $1.27 million grant from the United States Department of Defense to develop treatment for a rare but devastating eye condition largely affecting military personnel who suffer traumatic eye injuries in combat.
The fourth annual Weill Cornell Medicine Dean’s Symposium on Entrepreneurship and Academic Drug Development drew 125 attendees and served as an urgent reminder of the importance of biomedical innovation.
Cornell Tech’s first virtual Open Studio – an end-of-semester event in which students present the products they built to members of the tech industry – will be held online May 15.
Acinetobacter pittii (A. pittii), a type of bacteria, is evolving to become more resistant to antibiotics and is finding ways to survive in the harsh environment of the International Space Station, according to new research led by Weill Cornell Medicine scientists.
A growth factor protein produced by rare immune cells in the intestine can protect against the effects of inflammatory bowel disease, according to a new discovery from Weill Cornell Medicine researchers.
The Partners of Citadel and Citadel Securities have made a $2 million gift to Weill Cornell Medicine to develop new approaches to protect people from COVID-19 and identify new cases of it.
